Partial characterization of lipids that develop during the routine storage of blood and prime the neutrophil NADPH oxidase.
Factors developed during the routine storage of whole blood and packed red blood cells that primed the neutrophil (PMN) reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase significantly by 2 weeks of storage, with maximal priming activity by product outdate (2.5 to 3.7 fold). These agents appeared to be generated by cellular constituents because stored, acellular plasma did not demonstrate PMN priming. The priming activity was soluble in chloroform. Priming of the oxidase by plasma and plasma extracts was inhibited by WEB 2170, a platelet-activating factor (PAF) receptor antagonist. Separation of the chloroform-soluble compounds from plasma by normal phase high-performance liquid chromatography demonstrated two peaks of priming activity at the retention times of neutral lipids and lysophosphatidylcholines (lyso-PCs) for both whole blood and packed red blood cells. Analysis of the latter peak of PMN priming by fast atom bombardment mass spectroscopy identified several specific lyso-PC species including C16 and C18 lyso-PAF. Further evaluation by gas chromatography/mass spectroscopy demonstrated that three of these species increased dramatically over product storage time, while the other two species increased modestly, and paralleled the increase in priming activity. Commercially available, purified mixtures of these lyso-PCs primed the PMN oxidase by twofold. When PMNs were incubated with this mixture of lyso-PCs, acetylated analogs of these compounds rapidly accumulated. Thus lipids, including specific lyso-PC species, develop during routine storage of cellular blood components, prime PMNs, and possibly play a role in the severe complications of transfusion therapy.
Silliman
C C
CC
Department of Pediatrics, University of Colorado School of Medicine.
Clay
K L
KL
Thurman
G W
GW
Johnson
C A
CA
Ambruso
D R
DR
D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase; D000107:Acetylation; D001381:Azepines / Q000494:pharmacology; D001769:Blood / Q000187:drug effects; D001793:Blood Preservation; D004912:Erythrocytes / Q000187:drug effects; D006801:Humans; D008055:Lipids / Q000502:physiology*; D008244:Lysophosphatidylcholines / Q000097:blood / Q000378:metabolism; D009247:NADH, NADPH Oxidoreductases / Q000378:metabolism*; D019255:NADPH Oxidases; D009504:Neutrophils / Q000201:enzymology* / Q000378:metabolism; D010088:Oxidoreductases / Q000378:metabolism; D010741:Phospholipases A / Q000378:metabolism; D010949:Plasma / Q000502:physiology; D014230:Triazoles / Q000494:pharmacology
D001381:Azepines; D008055:Lipids; D008244:Lysophosphatidylcholines; D014230:Triazoles; C006065:We 201; C063964:bepafant; D010088:Oxidoreductases; D009247:NADH, NADPH Oxidoreductases; D019255:NADPH Oxidases; D010741:Phospholipases A; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase